IGC Pharma
Develops an investigational oral THC-and-melatonin therapy for Alzheimer’s-dementia agitation.
Something off on this page? Send us feedback.
Profile
Develops an investigational oral THC-and-melatonin therapy for agitation associated with Alzheimer’s dementia, alongside preclinical compounds and AI/data platforms. The small commercial stream comes from white-label and wellness products, while drug commercialization depends on trial results, regulatory approval, and third-party manufacturing.
Develops IGC-AD1, an investigational oral THC-and-melatonin solution for agitation associated with Alzheimer’s dementia, while advancing preclinical TGR-63 and IGC-M3 and building the MINT-AD and AHA data platforms. The commercial stream consists of white-label services and wellness and lifestyle products rather than pharmaceutical sales, and the company reports a single Life Sciences segment.
Operates from Potomac, Maryland, with activities across the United States, Canada, Colombia, and India, combining internal clinical operations and data management with external sites, CROs, vendors, and regulatory consultants. It has no approved drug or in-house manufacturing following the Vancouver asset sale; any approved-product commercialization would require third-party manufacturing or strategic partners. IGC-AD1 and its regulatory path are the central near-term dependencies.
Company facts
Key statistics
Year to date +6.0% · Average volume (30d) 825.6K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026Q1 FY27 | −$0.02 | −$0.03 | −50.0% | $164.0K | $265.0K | +61.6% | +1.29% |
| May 15, 2026Q4 FY26 | −$0.02 | −$0.02 | 0.0% | $198.0K | $317.0K | +60.1% | 0.00% |
| Apr 3, 2026Q3 FY26 | −$0.02 | −$0.02 | 0.0% | $250.0K | $246.5K | −1.4% | +1.13% |
| Nov 14, 2025Q2 FY26 | −$0.02 | −$0.02 | 0.0% | $383.0K | $191.0K | −50.1% | −5.03% |
Financial highlights
| 12 quarters | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|---|---|---|
| Revenue | $330.0K | $328.0K | $191.0K | $350.0K | $317.0K | $265.0K | |
| Gross profit | $154.0K | $154.0K | $99.0K | $44.0K | $55.0K | $48.0K | |
| Operating income | −$1.4M | −$1.9M | −$2.9M | −$2.9M | −$2.5M | −$2.8M | |
| Net income | −$1.2M | −$1.6M | −$1.8M | −$726.0K | −$2.4M | −$2.9M | |
| Diluted EPS | −$0.02 | −$0.02 | −$0.02 | −$0.01 | −$0.03 | −$0.03 | |
| Gross margin | 46.7% | 47.0% | 51.8% | 12.6% | 17.4% | 18.1% | |
| Operating margin | -427.9% | -580.8% | -1,517.8% | -840.3% | -775.4% | -1,050.6% |
Fiscal years (4-quarter sums)FY24 $1.3M · FY25 $1.3M · FY26 $1.2M
Revenue by product · FY25
Revenue by geography · Q4 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $354.0K · Total debt $1.1M · Total assets $9.5M · Shareholders' equity $6.1M
Dividends
No dividends on record.
Ownership
Shares outstanding 100.09M · Float 86.08M · 86.0% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Geode Capital Management, LLC | 1.04M | 1.04% | 13F | May 15, 2026 |
| Vanguard Capital Management LLC | 718.4K | 0.72% | 13F | May 15, 2026 |
| BlackRock, Inc. | 703.8K | 0.70% | 13F | May 13, 2026 |
| Renaissance Technologies LLC | 484.0K | 0.48% | 13F | May 14, 2026 |
| Vanguard Fiduciary Trust Co | 415.9K | 0.42% | 13F | May 8, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- Axsome Therapeutics
Approved non-antipsychotic rival in Alzheimer's agitation.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| IGC Pharma | $0.3107 | +1.04% | $31.0M | — | — | 27.6 | −19.2% |
| Axsome Therapeutics | $199.00 | −0.04% | $10.24B | — | 1,707.6 | 13.2 | +44.2% |
| Median | — | 1,707.6 | 13.2 | +44.2% |